


Stabilis



Ceftriaxone disodium



Noms commerciaux

Acantex	Argentine, Chili
Amcef	Mexique
Antibacin	Grèce
Aurofox	
Axobat	Italie
Azatyl	Grèce
Baktisef	Turquie
Biotrakson	Pologne
Bixon	Italie
Bresec	Grèce
Cefaday	Turquie
Cefonova	Suède
Cefotrix	Allemagne, Autriche, Danemark
Cefrag	Italie
Cephaxon	Turquie
Davixon	Italie
Daytrix	Italie
Deixim	Italie
Desefin	Turquie
Eftry	Italie
Eqicept	Turquie
Farcef	Grèce
Fidato	Italie
Forsef	Turquie
Frineg	Italie
Gladius	Grèce
Glorixone	Grèce
Kappacef	Italie
Labilex	Grèce
Lendacin	Croatie, Pologne, Russie, Slovénie
Lidacef	Croatie
Mesporin	Arabie Saoudite, Portugal
Nevakson	Turquie
Nilson	Italie
Novocef	Turquie
Oframax	Texte introuvable (616,), Pologne
Olisef	Slovénie
Panatrix	Italie
Pantoxon	Italie
Ragex	Italie
Rocefalin	Espagne
Rocefin	Brésil, Italie

Rocephalin	Danemark, Finlande, Norvège, Suède
Rocephin	Afrique du sud, Allemagne, Canada, Etats Unis d'Amérique, Grèce, Pays bas, Pologne, Portugal, Suisse, Thaïlande, Turquie
Rocephine	Allemagne, Belgique, France
Sirtap	Italie
Tartriakson	Pologne
Tercefon	Autriche
Travilan	Grèce
Unacefin	Turquie
Valexime	Italie



Stabilité des solutions

		10 & 50 mg/ml	-20°C		182			589
		10 mg/ml	5°C		21			589
		10 & 50 mg/ml	15°C-32°C		7			589
		20 mg/ml	2-8°C		28			1452
		20 mg/ml	25°C		24			432
		20 mg/ml	25°C		5			1452
		50 mg/ml	5°C		35			589
		10 mg/ml	15°C-32°C		7			589
		10 mg/ml	5°C		84			589
		20 mg/ml	25°C		48			432
		50 mg/ml	15°C-32°C		24			589
		50 mg/ml	5°C		56			589
		40 mg/ml	23°C		3			640
		40 mg/ml	4°C		30			640
		2 mg/ml	-20°C		14			587
		2 mg/ml	20°C		14			587
		2 mg/ml	4°C		14			587
		40 mg/ml	23°C		1			640
		40 mg/ml	4°C		14			640

		20 mg/ml	-20°C		98			2110
		20 mg/ml	2-8°C		14			2110
		20 mg/ml	2-8°C		28			1452
		20 mg/ml	25°C		5			1452
		10 & 20 mg/ml	23°C		3			1840
		10 & 20 mg/ml	4°C		30			1840
		100 mg/ml	-20°C		180			100
		100 mg/ml	20°C		5			100
		100 mg/ml	4°C		40			100
		100 mg/ml	8°C		13			1638
		10 & 40 mg/ml	-15°C		10			259
		250 & 450 mg/ml	-15°C		56			279
		250 & 450 mg/ml	20°C		24			279
		250 & 450 mg/ml	4°C		10			279
		250 mg/ml	-15°C		56			279
		250 & 450 mg/ml	20°C		24			279
		250 & 450 mg/ml	4°C		10			279
		5 & 40 mg/ml	25°C		24			604
		5 & 40 mg/ml	4°C		10			604



Stabilité en mélange

		20 mg/ml	25°C		Clindamycin phosphate : 12 mg/ml	8		432
		20 mg/ml	25°C		Clindamycin phosphate : 12 mg/ml	1		432
		10 mg/ml	24-26°C		Metronidazole : 7,5 mg/ml	24		11
		10 mg/ml	4-6°C		Metronidazole : 7,5 mg/ml	72		11
		10 mg/ml	25°C		Metronidazole : 5 mg/ml	3		649
		10 mg/ml	8°C		Metronidazole : 5 mg/ml	72		282
		450 mg/ml	-15°C		Lidocaine hydrochloride : 10 mg/ml	56		279
		450 mg/ml	20°C		Lidocaine hydrochloride : 10 mg/ml	24		279
		450 mg/ml	4°C		Lidocaine hydrochloride : 10 mg/ml	10		279
		40 mg/ml	25°C		Paracetamol : 10 mg/ml	4		3571



Facteur influençant la stabilité

				589
	RL			1744
	RL			3523
				2238
				3523
				100



Compatibilités











	Ceftriaxone disodium : 20 mg/ml Aciclovir sodium : 5 mg/ml		336
	Ceftriaxone disodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
	Ceftriaxone disodium : 20 mg/ml Amifostine : 10 mg/ml		3
	Ceftriaxone disodium Amikacin sulfate		3523
	Ceftriaxone disodium : 20 & 40 mg/ml Aminophylline : 1 & 4 mg/ml		276
	Ceftriaxone disodium : 20 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
	Ceftriaxone disodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	Ceftriaxone disodium : 20 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Ceftriaxone disodium : 40 mg/ml Amsacrine : 1 mg/ml		253
	Ceftriaxone disodium : 20 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Ceftriaxone disodium : 66.7 mg/ml Azithromycine : 2 mg/ml		1800
	Ceftriaxone disodium : 20 mg/ml Aztreonam : 40 mg/ml		99
	Ceftriaxone disodium : 20 mg/ml Bivalirudin : 5 mg/ml		1713
	Ceftriaxone disodium : 50 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
	Ceftriaxone disodium Calcium glucoheptonate		3523

	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 40 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 20 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 20 mg/ml Clindamycin phosphate : 12 mg/ml		432
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 100 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 16,7 mg/ml Daptomycin : 16,7 mg/ml		1937
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
	<input checked="" type="checkbox"/>	Ceftriaxone disodium	RL	1744
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 20 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 100 mg/ml		939
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 100 mg/ml		150
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Amsacrine		3523
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Calcium chloride		3523
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Calcium gluconate		3644
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Calcium gluconate		2302
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Clindamycin phosphate		3526
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 20 mg/ml		301
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Calcium gluconate		3523
	<input checked="" type="checkbox"/>	Ceftriaxone disodium		3523
	<input checked="" type="checkbox"/>	Ceftriaxone disodium	RL	3523
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 100 mg/ml Caffeine : 10 mg/ml		3964
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 20 mg/ml		1415
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 10 mg/ml		4440
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Amikacin sulfate		3549
	<input checked="" type="checkbox"/>	Ceftriaxone disodium		3523
	<input checked="" type="checkbox"/>	Ceftriaxone disodium		2238
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 100 mg/ml	RL	4603
	<input checked="" type="checkbox"/>	Ceftriaxone disodium : 20 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
	<input checked="" type="checkbox"/>	Ceftriaxone disodium Daptomycin		2271

		Ceftriaxone disodium : 100 mg/ml Defibrotide : 8 mg/ml		3728
		Ceftriaxone disodium : 20 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Ceftriaxone disodium : 40 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Ceftriaxone disodium : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Ceftriaxone disodium : 20 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Ceftriaxone disodium Erythromycin lactobionate		3674
		Ceftriaxone disodium : 20 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Ceftriaxone disodium : 20 mg/ml Famotidine : 2 mg/ml		215
		Ceftriaxone disodium : 20 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Ceftriaxone disodium : 20 mg/ml Filgrastim : 30 µg/ml		244
		Ceftriaxone disodium : 40 mg/ml Fluconazole : 2 mg/ml		496
		Ceftriaxone disodium Fluconazole		3523
		Ceftriaxone disodium : 20 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Ceftriaxone disodium Folinate calcium		3523
		Ceftriaxone disodium : 20 mg/ml Foscarnet sodium : 24 mg/ml	 	1135
		Ceftriaxone disodium : 20 mg/ml Fosfomycin : 30 mg/ml	 	4055
		Ceftriaxone disodium : 40 mg/ml Gallium nitrate : 1 mg/ml		91
		Ceftriaxone disodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Ceftriaxone disodium Gentamicin sulfate		3643
		Ceftriaxone disodium Gentamicin sulfate		3520
		Ceftriaxone disodium Gentamicin sulfate		3523
		Ceftriaxone disodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Ceftriaxone disodium : 20 mg/ml Heparin sodium : 50 UI/ml		317
		Ceftriaxone disodium : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Ceftriaxone disodium : 10 & 50 mg/ml Insulin aspart : 1 UI/ml	 	1508
		Ceftriaxone disodium : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml	 	3829

		Ceftriaxone disodium Kanamycin sulfate		3523
		Ceftriaxone disodium : 40 mg/ml Ketoprofene : 3.2 mg/ml		1847
		Ceftriaxone disodium : 20 mg/ml Labetalol hydrochloride : 5 & 2,5 mg/ml		241
		Ceftriaxone disodium : 100 mg/ml Labetalol hydrochloride : 5 & 2,5 mg/ml		241
		Ceftriaxone disodium : 20 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Ceftriaxone disodium Levofolinate calcium	RL	3523
		Ceftriaxone disodium Levofolinate calcium		3523
		Ceftriaxone disodium Linezolid		3560
		Ceftriaxone disodium : 10 mg/ml Linezolid : 2 mg/ml		1659
		Ceftriaxone disodium : 20 mg/ml Linezolid : 2 mg/ml		1925
		Ceftriaxone disodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
		Ceftriaxone disodium : 100 mg/ml Meropenem : 50 mg/ml		4319
		Ceftriaxone disodium : 100 mg/ml Methotrexate sodium : 30 mg/ml		150
		Ceftriaxone disodium : 20 mg/ml Metronidazole : 15 mg/ml		11
		Ceftriaxone disodium : 10 mg/ml Metronidazole : 7.5 mg/ml		11
		Ceftriaxone disodium : 10 mg/ml Metronidazole : 5 mg/ml		282
		Ceftriaxone disodium : 10 mg/ml Metronidazole : 5 mg/ml		649
		Ceftriaxone disodium : 20 mg/ml Milrinone lactate : 0,2 mg/ml		4144
		Ceftriaxone disodium : 20 & 40 mg/ml Morphine sulfate : 1 mg/ml		62
		Ceftriaxone disodium N-acetylcysteine : 200 mg/ml		3766
		Ceftriaxone disodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Ceftriaxone disodium Netilmicin sulfate		3523
		Ceftriaxone disodium : 20 mg/ml Paclitaxel : 1.2 mg/ml		248
		Ceftriaxone disodium : 20 >> 40 mg/ml Pantoprazole sodium : 0.16 >> 0.8 mg/ml		1902
		Ceftriaxone disodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Ceftriaxone disodium : 40 mg/ml Paracetamol : 10 mg/ml		3571

		Ceftriaxone disodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Ceftriaxone disodium : 20 mg/ml Pentamidine isetionate : 3 mg/ml		275
		Ceftriaxone disodium : 20 & 40 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Ceftriaxone disodium : 20 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Ceftriaxone disodium Plazomicin sulfate		3523
		Ceftriaxone disodium : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Ceftriaxone disodium : 20 mg/ml Propofol : 10 mg/ml		300
		Ceftriaxone disodium : 20 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Ceftriaxone disodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Ceftriaxone disodium : 20 mg/ml Sargramostim : 10 µg/ml		335
		Ceftriaxone disodium : 100 mg/ml Sodium bicarbonate : 14 mg/ml		150
		Ceftriaxone disodium Streptomycin sulfate		3523
		Ceftriaxone disodium : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Ceftriaxone disodium : 40 mg/ml Tacrolimus : 1000 µg/ml		479
		Ceftriaxone disodium : 20 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Ceftriaxone disodium : 20 mg/ml Telavancin hydrochloride : 7.5 mg/ml	 	3254
		Ceftriaxone disodium : 20 mg/ml Teniposide : 0.1 mg/ml		905
		Ceftriaxone disodium : 20 & 40 mg/ml Theophylline : 4 mg/ml	 	276
		Ceftriaxone disodium : 20 mg/ml Theophylline : 4 mg/ml		317
		Ceftriaxone disodium : 100 mg/ml Thiopental sodium : 25 mg/ml		3767
		Ceftriaxone disodium : 20 mg/ml Thiotepa : 1 mg/ml		249
		Ceftriaxone disodium Tobramycin sulfate		3523
		Ceftriaxone disodium : 1 >> 250 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Ceftriaxone disodium Vancomycin hydrochloride		3523
		Ceftriaxone disodium : 100 mg/ml Vancomycin hydrochloride : 20 mg/ml		95
		Ceftriaxone disodium : 1 >> 250 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674

		Ceftriaxone disodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Ceftriaxone disodium : 20 mg/ml Warfarin sodium : 2 mg/ml		315
		Ceftriaxone disodium : 20 mg/ml Zidovudine : 4 mg/ml		337
		Ceftriaxone disodium : 0,22 mg/ml	 	4693



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
11	Revue	Bailey LC, Orosz ST. Stability of ceftriaxone sodium and metronidazole hydrochloride. Am J Health-Syst Pharm 1997 ; 54: 424-427.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
95	Revue	Pritts D, Hancock D. Incompatibility of ceftriaxone with vancomycin. Am J Hosp Pharm 1991 ; 48: 77.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
100	Revue	Plumridge RJ, Rieck AM, Annus TP, Langton SR. Stability of ceftriaxone sodium in polypropylene syringes at -20, 4, and 20°C. Am J Health-Syst Pharm 1996 ; 43: 2320-2323.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.

169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
241	Revue	Leader WG, Jones JM. Incompatibility between ceftriaxone sodium and labetalol hydrochloride. Am J Health-Syst Pharm 1996 ; 53: 2639.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
259	Revue	Bailey LC, Tang KT, Medwick T. Stability of ceftriaxone sodium in infusion-pump syringes. Am J Hosp Pharm 1993 ; 50: 2092-2094.
275	Revue	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
276	Revue	Parrish MA, Bailey LC, Medwick T. Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures. Am J Hosp Pharm 1994 ; 51: 92-94.
279	Revue	Bailey LC, Cappel KM, Orosz ST. Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes. Am J Hosp Pharm 1994 ; 51: 2159-2161.
282	Revue	Rivers TE, Webster AA. Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 2568-2570.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
432	Revue	Marble DA, Bosso JA, Townsend RJ. Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm 1986 ; 43: 1732-1736.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
587	Revue	Smith BR. Effect of storage temperature and time stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection. Am J Hosp Pharm 1983 ; 40: 1024-1025.
589	Revue	Kedzierewicz F, Finance C, Nicolas A, Dixneuf P, Hoffman M. Stability of parenteral ceftriaxone disodium solutions in frozen and liquid states: effect of freezing and microwave thawing. J Pharm Sci 1989 ; 78: 73-77.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
640	Revue	Walker SE, Dranitsaris G. Stability of reconstituted ceftriaxone in dextrose and saline solutions. Can J Hosp Pharm 1987 ; 40: 161-166.

649	Revue	Das Gupta V. Stability of ceftriaxone sodium when mixed with metronidazole injection. Int J Pharm Compound 1997 ; 1: 280-281.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	Revue	Muller HJ, Howe K, Frank C, Haker I. Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1638	Revue	O'Connell C, Sabra K, Scott K. Stability of reconstituted ceftriaxone solution in polypropylene syringes. Eur Hosp Pharm 1996 ; 2: 47-48.
1659	Revue	Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics. J Am Pharm Assoc 2000 ; 40: 509-514.
1674	Revue	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.

1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1744	Revue	Burkiewicz JS. Incompatibility of ceftriaxone sodium with lactated Ringer's injection. Am J Health-Syst Pharm 1999 ; 56: 384.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1840	Revue	Xu QA, Trissel LA, Saenz CA et al. Stability of three cephalosporin antibiotics in autodose infusion system bags. J Am Pharm Assoc 2002 ; 42: 428-431.
1847	Revue	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen lysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	Revue	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2110	Revue	Hecq JD, Evrard JM, Vanbeckbergen DF, Jamart J, Galanti LM. Effect of freezing, long term storage and microwave thawing on the stability of ceftriaxone sodium in 5% dextrose infusion polyolefin bags at 2-8°C. EJHP Science 2006 ; 12, 3: 52-56.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2238	Laboratoire	Clinomel - Résumé des caractéristiques du produit Baxter 2018
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.

2271	Laboratoire	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2302	Laboratoire	Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium.
3012	Revue	Sullivan AF, Saps J, Novick J. Evaluation of Physical Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3523	Laboratoire	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3560	Laboratoire	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98

3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4144	Revue	Ross A, Boddu S, Mauro V, Churchwell M. Physical compatibility of milrinone with levofloxacin and ceftriaxone injection. EJHP 2018 ;75,14:1010-1012
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4693	Revue	Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L. Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection. Drug Design Dev Ther 2022 ;16:1433-1440.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	Antibiotique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	NaCl 0,9% ou glucose 5%		A l'abri de la lumière
	Jour		Chlorure de sodium 0,9%
	Non précisée		Lumière
	Heure		Glucose 5%
	Polyvinyl chlorure		Polyéthylène
	Polyolefine		Ethylène vinyl acétate
	Seringue polypropylène		Eau pour préparation injectable
	Eau ppi + bactériostatique		Elastomère en polyisoprène
	Stabilité en mélange		Solvant
	Molécule		Aucun
	Polypropylène		Non précisé
	Facteur influençant la stabilité		Provoque
	Augmentation stabilité		Ringer lactate
	Précipitation		Dégradation
	Nutrition parentérale (mélange ternaire)		Nutrition parentérale (mélange binaire)
	Augmentation		Compatibilités
	Compatible		Incompatibilité non précisée
	Incompatible		Instabilité chimique
	Perte de turbidité		Précipitation immédiate
	NaHCO3		Précipitation en 1 heure
	Solvant spécifique		Turbidité immédiate
	NaCl 0.225 % + glucose 3.75%		Voie d'administration
	Intraveineuse		Perfusion intraveineuse



Intramusculaire



Dictionnaire



Bibliographie